Your prediction
Pros and Cons of Amp Ltd. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amp Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amp Ltd. | 5.300% | 20.870% | 40.404% | 51.087% | 34.951% | 115.504% | 109.023% |
| National Australia Bank | 0.980% | 2.857% | 12.889% | 19.697% | 9.918% | 57.343% | 56.851% |
| Commonwealth Bank Australia | 1.250% | -0.398% | 9.649% | 9.431% | 19.930% | 81.279% | 69.622% |
| Macquarie Group Ltd | 0.160% | 5.593% | 6.717% | 35.232% | 39.893% | 56.115% | 64.933% |
News
Ardagh Metal Packaging Q2 Earnings Call Highlights
Key Points
- Interested in Ardagh Metal Packaging S.A.? Here are five stocks we like better.
- Ardagh Metal Packaging raised full-year 2026 adjusted EBITDA guidance to $775 million-$790 million
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
Key Points
- Interested in Amphastar Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amphastar is shifting its strategy from complex generics toward proprietary drugs and
Pennon Group H2 Earnings Call Highlights
Key Points
- Interested in Pennon Group Plc? Here are five stocks we like better.
- Pennon returned to profitability in 2025/2026, with EBITDA up 55% and underlying operating profit more than